Parsey Merdad

Chief Medical Officer Parsey Merdad sells 164,211 shares ($15.1M) across 5 transactions at $91.79–$92.00, reducing holdings by 67.0%

Parsey Merdad, Chief Medical Officer at Gilead Sciences, executed 5 separate sales totaling 164,211 shares for $15,094,013.40 at a blended average price of $91.92 on 2024-11-27, reducing his holdings from 245,012 shares to 80,801 shares (a 67.0% reduction of pre-transaction holdings). The stock is currently trading at $92.58, near the transaction prices. His cross-ticker track record shows a 90-day well-timed rate of 100.00% across 5 prior sells with an average 90-day return of -12.7%, and his same-ticker history at GILD across 5 prior trades shows 2 measurable 90-day outcomes, both negative (-12.7% and -12.6%), suggesting a pattern of selling ahead of declines. The magnitude of this divestment—eliminating two-thirds of his position—combined with the consistent pattern of well-timed prior sales, warrants close observation of subsequent quarterly performance and any forward-looking guidance changes at the company.

Parsey Merdad (CMO) sells 25,590 shares at $91.50 for $2,341,485.00; stock now trades at 52-week high of $97.90, +14.9% in 30 days.

Parsey Merdad, Chief Medical Officer of Gilead Sciences, executed 2 separate sales totaling 25,590 shares for $2,341,485.00 on 2024-11-06, reducing his holdings by 20.4% from 125.2K to 99.6K shares. The sales occurred at $91.50 per share while the stock has since appreciated to $97.90, now at its 52-week high, with 30-day and 90-day gains of 14.9% and 32.9% respectively. His prior trades at Gilead showed strong 90-day timing, with 2 of 2 measurable sales preceded declines, yet this current sale was made near the stock's 52-week peak amid sustained momentum—a materially different technical setup than his previous opportunities. The unusually high P/E of 115.18 combined with near-flat annual revenue growth of -0.6% and the CMO's sizable position reduction warrant investor attention to the divergence between valuation metrics and execution timing.

Gilead CMO Parsey Merdad sells 21,246 shares ($1.8M) at $84.50; stock up 27.3% in 90 days

Parsey Merdad, Chief Medical Officer of Gilead Sciences, sold 21,246 shares for $1,795,287.00 at $84.50 on 2024-09-12, reducing holdings by 17.2% from 123,435 to 102,189 shares. This sale occurred after significant recent price momentum, with the stock up 27.3% over the prior 90 days and trading only 5.1% below its 52-week high of $87.29. Notably, Merdad's cross-ticker track record shows 2 prior sells with a well-timed rate of 100.00%, and his prior trades at Gilead (both February 2024 sells) were similarly well-timed at the 90-day mark, each posting negative 90-day returns of -12.7% and -12.6% respectively. The timing of this current sale—near recent highs and after substantial gains—follows his demonstrated pattern of selling before subsequent declines, though the fundamental backdrop shows Gilead generating $7.0B in quarterly revenue and $1.6B in net income, albeit with flat annual revenue growth (-0.6%) and a notably elevated P/E of 97.42.